AllianceBernstein to sue Switzerland over $17 bln Credit Suisse debt wipeout, FT reports-February 2024-www.financetom.com

AllianceBernstein to sue Switzerland over $17 bln Credit Suisse debt wipeout, FT reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AllianceBernstein to sue Switzerland over $17 bln Credit Suisse debt wipeout, FT reports

Dec 9, 2024 9:22 PM

Dec 10 (Reuters) - U.S. asset manager AllianceBernstein ( AB )

is preparing to sue Switzerland for $225 million over the

decision to wipe out $17 billion of debt when the country's

government orchestrated the takeover of Credit Suisse by rival

UBS last year, the Financial Times reported on Tuesday.

Previous page： Singapore's Keppel files for $53 million claim against Seatrium over Brazil corruption case Next page： Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Singapore's Keppel files for $53 million claim against Seatrium over Brazil corruption case

Aug 26, 2025

(Reuters) -Singapore's Keppel has initiated arbitration proceedings against local shipbuilder Seatrium for a S$68.4 million ($53.33 million) claim related to a corruption crackdown in Brazil, the companies said on Tuesday. In 2022, Seatrium had made provisions worth S$82.4 million to pay Keppel against claims related to the crackdown, named Operation Car Wash. Seatrium noted the obligation to pay Keppel expired...

Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study

Aug 26, 2025

07:54 AM EDT, 08/26/2025 (MT Newswires) -- Marker Therapeutics ( MRKR ) said Tuesday its investigational therapy MT-601 achieved a 66% objective response rate in patients with relapsed non-Hodgkin lymphoma, and 50% showed a complete response. In the phase 1 study, eight out of 12 non-Hodgkin lymphoma patients responded to treatment, including six with complete responses, Marker Therapeutics ( MRKR...

Regeneron Says Cemdisiran Monotherapy Meets Primary, Key Secondary Endpoints in Late-Stage Trial in Generalized Myasthenia Gravis Patients

Aug 26, 2025

07:54 AM EDT, 08/26/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Tuesday that its investigational cemdisiran monotherapy met the primary and key secondary endpoints in a late-stage trial in adults with generalized myasthenia gravis. The company said Cemdisiran monotherapy showed a 2.3-point placebo-adjusted improvement in MG-ADL total score. Detailed results from the trial will be presented at an...

MCF Energy Increased Financing To $1.2 Million

Aug 26, 2025

07:55 AM EDT, 08/26/2025 (MT Newswires) -- MCF Energy ( MCFNF ) overnight Monday increased its previously announced non-brokered financing from $500,000 to $1,200,000. A statement noted the Offering will consist of 24 million units at a price of $0.05 per Unit. Each Unit will consist of one common share and one full common share purchase warrant with each warrant...